Targeted Therapy to Improve Radioactive Iodine Uptake in Patients with Metastatic Differentiated Thyroid Cancer

What this Trial Is About

Papillary thyroid cancer PTC is a common type of differentiated thyroid cancer DTC in children and is the second most common cancer in adolescent females. Researchers are evaluating how targeted drugs that block genetic drivers of DTC affect the uptake of radioactive iodine RAI in tumors, as this impact has not been systematically studied before. The study focuses on patients with metastatic DTC in the lungs receiving these targeted therapies. This observational cohort study enrolls patients receiving oncogene-specific targeted therapy either through routine clinical care or separate therapeutic clinical trials. Patients undergo a baseline whole body radioactive iodine scan before starting therapy and then receive approximately 4 weeks of targeted treatment. After therapy, a second whole body scan is done to assess any changes in RAI-avidity of the tumor. Subsequent treatments are decided by the treating physician or based on the other therapeutic trial the patient may be enrolled in. Participants will have scans performed before and about 28 days after starting targeted therapy to evaluate tumor changes. Researchers measure the proportion of patients whose tumors show increased RAI-avidity after therapy over up to 5 years. The study involves data sharing for those on other targeted therapy trials who agree to share their scan results. Safety monitoring excludes certain groups such as pregnant or breastfeeding females and those needing sedation for scans. The study may continue for several years to observe outcomes.

Targeted Therapy to Increase RAI Uptake in Metastatic DTC